The original success of the copyright undeniably reshaped the drug landscape, but investing in companies heavily reliant on off-patent versions presents a challenging picture. While early returns were significant, the end of patents and the rise of less expensive alternatives have weakened market share. Thus, a thorough assessment of current revenu